Tempo Acquires ALM Works to Deliver Integrated Strategic Portfolio Management Offering
22.12.2021 20:17:00 EET | Business Wire | Press release
Tempo Software, the leader in team time management and productivity-enhancing solutions, today announced the acquisition of ALM Works, developer of the Structure for Jira software suite that enables project and program managers to make better decisions, work more efficiently, and deliver predictable results. A top-selling project management solution, ALM Works helps over 5000 organizations worldwide visualize, track and manage progress across large-scale, complex projects. Tempo and ALM Works together will provide the first suite of purpose-built program management apps to meet project, program and portfolio management needs for over 70 million users within the Atlassian Ecosystem.
The combination of Tempo’s team time and capacity management solutions and ALM Works’ project and artifact structuring solutions will enable program managers to easily understand whether key initiatives are on track and meeting strategic objectives. A recent Tempo survey showed that 55% of software development executives reported that they use time tracking insights to inform project and portfolio management. This new combination of Tempo and ALM Works will provide organizations with the visibility required to move between strategy and daily execution, make informed decisions, and share progress with executives and stakeholders.
“For over a decade, ALM Works has set themselves apart within the Atlassian Ecosystem due to their focused efforts on helping bring structure to complex project data,” said Mark Lorion, CEO, Tempo Software. “Through an even tighter integration with ALM Works, we are excited to bring a modern, easy-to-use and scalable program management solution to market and to our many shared customers and partners. Together we will uniquely support the teams who operate within Jira on a daily basis and provide the data that senior leadership teams need to be responsive as they set product strategy for an organization.”
“ALM Works focuses on enabling project and program managers to solve complex problems with our flexible, adaptable Structure solution,” said Igor Sereda, ALM Works CEO. “By bringing ALM Works together with Tempo’s industry-leading time tracking and productivity management suite of products, we’re now well-positioned to deliver the most comprehensive program and portfolio management offering to the market. I am proud of the work our team has accomplished over the past 17 years and look forward to bringing visibility and strategic insights to even more people and teams.”
Combined with the recent acquisition of Roadmunk, the addition of ALM Works strengthens Tempo’s strategic portfolio management offering. As a modern and integrated solution suite, Tempo will meet the growing needs of today’s distributed and complex product organizations who need to project, plan, and adapt based on timely organizational capacity data and insights.
Supporting Resources:
- ALM Works website: https://almworks.com/
- Tempo website: https://www.tempo.io
- ALM Works blog: https://almworks.com/blog.html
- Tempo blog: https://www.tempo.io/blog
About Tempo
Tempo Software offers integrated applications for time management, resource planning, and budget management for software engineering and product management teams. Our customers gain an unrivaled understanding of time and effort, and they improve how their teams plan and manage their work. This provides an aligned understanding of and plan for how time –the most precious, and finite resource–is optimized. Tempo Software is seamlessly integrated across popular DevOps tools and a natural and automated part of users’ workflows.
Headquartered in Boston and with offices in Reykjavik, Iceland and Montreal, Canada, Tempo Software is one of the largest and most successful companies in the Atlassian ecosystem.
Tempo has more than 20,000 customers across a range of industries in more than 100 countries. It works with hundreds of partners around the world, offering resale, training, and consultancy in local languages. Tempo is available in English, French, German, Spanish, Portuguese, and Russian, with Japanese coming soon. To learn more about Tempo, visit www.tempo.io
About ALM Works
ALM Works provides software products to empower project managers around the world with visibility and control. ALM Works’ flagship product, Structure for Jira, is a project and portfolio management tool for Atlassian, used by thousands of customers in over 100 countries. Structure, together with its extensions such as Structure.Gantt, is made for project managers and other people responsible for planning, tracking, and getting things done at an organization. It allows them to work efficiently, deliver predictable results, see problems earlier, make better decisions and communicate with clarity and confidence to their teams, managers and clients.
ALM Works is headquartered in Boston with offices in Saint-Petersburg, Russia. To learn more about ALM Works, visit almworks.com.
About Diversis Capital, L.P.
Founded in 2013, Diversis is a software and technology focused private equity fund with $1bn+ in AUM that invests in lower middle-market companies, targeting situations where it can add unique value in helping a company reach the next level. With a collaborative approach to investing, its Operating Partners and Strategic Advisors work alongside management teams to help build successful organizations positioned for long-term growth. To learn more, visit www.diversis.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005442/en/
Contact information
Escalate PR for Tempo.io
tempo@escalatepr.com
Joel Richman
joel@escalatepr.com
+1 617 312 5942
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
